William Blair upgraded Neuronetics from Market Perform to Outperform
Get the next $STIM alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $STIM
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | Outperform → Mkt Perform | William Blair | |
| 10/14/2021 | $18.00 → $12.00 | Market Outperform | JMP Securities |
| 10/13/2021 | Outperform → Mkt Perform | William Blair | |
| 10/13/2021 | Buy → Neutral | BTIG |
Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Acquired Greenbrook TMS on December 9, 2024Received an incremental $10 million in funding from Perceptive AdvisorsFourth quarter 2024 revenue of $22.5 million, a 11% increase as compared to the fourth quarter 2023U
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. Three of the RSU grants vests ratably i
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo
Neuronetics downgraded by William Blair
William Blair downgraded Neuronetics from Outperform to Mkt Perform
JMP Securities reiterated coverage on Neuronetics with a new price target
JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously
Neuronetics downgraded by William Blair
William Blair downgraded Neuronetics from Outperform to Mkt Perform
Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)
4 - Neuronetics, Inc. (0001227636) (Issuer)
Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)
4 - Neuronetics, Inc. (0001227636) (Issuer)
Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)
4 - Neuronetics, Inc. (0001227636) (Issuer)
Amendment: SEC Form 4 filed by President and CEO Sullivan Keith J
4/A - Neuronetics, Inc. (0001227636) (Issuer)
Amendment: SEC Form 4 filed by EVP, CFO and Treasurer Furlong Stephen
4/A - Neuronetics, Inc. (0001227636) (Issuer)
Amendment: SEC Form 4 filed by EVP, GC, CCO and CS Macan William Andrew
4/A - Neuronetics, Inc. (0001227636) (Issuer)
Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
8-K - Neuronetics, Inc. (0001227636) (Filer)
SEC Form 144 filed by Neuronetics Inc.
144 - Neuronetics, Inc. (0001227636) (Subject)
SEC Form 424B5 filed by Neuronetics Inc.
424B5 - Neuronetics, Inc. (0001227636) (Filer)
Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical
Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors
MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will
IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo
CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and ope
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024. Third Quarter 2024 Highlights Third quarter 2024 revenue of $18.5 million, a 4% increase as compared to the third quarter 2023U.S. NeuroStar Advanced Therapy system revenue of $4.1 million in the quarter, representing 48 systemsU.S. treatment session revenue increased by 2% versus the third quarter of
SEC Form SC 13D filed by Neuronetics Inc.
SC 13D - Neuronetics, Inc. (0001227636) (Subject)
Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)
Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.
SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)